1. Introductory Remarks

   • Perrin Beatty

   OriginalPaper 28 November 2012 Pages: 1 - 3

2. Safety by Design

   • David Jack

   OriginalPaper 28 November 2012 Pages: 4 - 23

3. Safety Considerations in Product Development

   • Arthur H. Hayes Jr

   OriginalPaper 28 November 2012 Pages: 24 - 26

4. In Vitro Models

   • Diana Anderson

   OriginalPaper 28 November 2012 Pages: 27 - 39

5. Animal Models

   • Gabriel L. Plaa

   OriginalPaper 28 November 2012 Pages: 40 - 45

6. The Evaluation of the Abuse Liability of Drugs

   • Chris E. Johanson

   OriginalPaper 28 November 2012 Pages: 46 - 57

7. Safety Evaluation of Biotechnology Products

   • G. Zbinden

   OriginalPaper 28 November 2012 Pages: 58 - 64

8. Therapeutic Challenges

   • Ralph E. Kauffman

   OriginalPaper 28 November 2012 Pages: 65 - 70

9. Research Challenges, New Drug Development, Preclinical and Clinical Trials in the Ageing Population

   • Darrell R. Abernethy

   OriginalPaper 28 November 2012 Pages: 71 - 74

10. Endogenous Substances as Drugs

    • David R. Parkinson

    OriginalPaper 28 November 2012 Pages: 75 - 83

11. Health Implications of Drug Interactions

    • M. N. G. Dukes

    OriginalPaper 28 November 2012 Pages: 84 - 87

12. Rational Limits for Drug Impurities

    • Barbara B. Hubert

    OriginalPaper 28 November 2012 Pages: 88 - 94

13. Non-Medicinal Ingredients

    • Alexander W. M. Scott

    OriginalPaper 28 November 2012 Pages: 95 - 100

14. Parenteral Nutrition

    • M. I. Barnett
    • A. G. Cosslett
    • D. R. Williams

    OriginalPaper 28 November 2012 Pages: 101 - 106

15. Pharmacology and Toxicology of Novel Drug Delivery Systems

    • Judi Weissinger

    OriginalPaper 28 November 2012 Pages: 107 - 113

16. Therapeutic Inequivalence

    • Peter H. Rheinstein

    OriginalPaper 28 November 2012 Pages: 114 - 119

17. Over-the-Counter Drugs

    • Hubertus Cranz

    OriginalPaper 28 November 2012 Pages: 120 - 125

18. The Harmful Potential of Herbal and Other Plant Products

    • Ryan J. Huxtable

    OriginalPaper 28 November 2012 Pages: 126 - 136

19. Pharmacovigilance

    • René Jean Royer

    OriginalPaper 28 November 2012 Pages: 137 - 140

20. Drug Safety in the European Community

    • Fernand Sauer

    OriginalPaper 28 November 2012 Pages: 141 - 148

21. Risk Assessment of Drugs

    • E. Somers

    OriginalPaper 28 November 2012 Pages: 149 - 154

22. Realities of Drug Use in Society

    • Frederick H. Lowy

    OriginalPaper 28 November 2012 Pages: 155 - 159

23. Long Term Caffeine Reduces Cerebral Ischaemic Damage

    • G. Sutherland
    • J. Peeling
    • Y. Geoffrion

    Short Communications 28 November 2012 Pages: 160 - 160

24. Cardiovascular Effects of Phenylpropanolamine

    • Frank R. Funderburk
    • Ann T. Summerfelt
    • Linda L. Weinhold

    Short Communications 28 November 2012 Pages: 160 - 161

25. Correlation of Histopathological Change with Urinary N-Acetyl Glucosaminidase (NAG) Levels in the Detection of Early Injury to Renal Tubules

    • M. H. Gregory
    • D. G. Wells

    Short Communications 28 November 2012 Pages: 161 - 161

26. Mammary Transmission of ³H-Cocaine-Derived Radioactivity in Suckling Rats

    • H. S. Buttar
    • J. H. Moffatt

    Short Communications 28 November 2012 Pages: 161 - 162

27. Cyclosporin-A Modifies the Metabolism of [2-¹³C]Pyruvate in the Liver of Mice

    • Y. Geoffrion
    • T. Kroft
    • R. Deslauriers

    Short Communications 28 November 2012 Pages: 162 - 162

28. Potential to Reduce the Impact of Phenytoin Adverse Reactions on Patient Care and Hospital Admissions

    • David Jaffe
    • Michael Davis
    • Ellen Monkus

    Short Communications 28 November 2012 Pages: 162 - 163

29. Application of a Bacterial Cell Reactivity Assay to the Evaluation of Drug Safety

    • T. I. Matula
    • R. J. Wood
    • D. W. Hughes

    Short Communications 28 November 2012 Pages: 163 - 163

30. A Potential Radioimmunoassay for Monitoring Salbutamol (Albuterol) Using a Monoclonal Antibody

    • A. Adam
    • K. Ong
    • N. Beaulieu

    Short Communications 28 November 2012 Pages: 163 - 164

31. Monitoring of Salbutamol (Albuterol) in Humans

    • H. Ong
    • A. Adam
    • J. C. K. Loo

    Short Communications 28 November 2012 Pages: 164 - 164

32. Specific Radioimmunoassay for Medroxyprogesterone Acetate

    • H. Ong
    • A. Adam
    • J. C. K. Loo

    Short Communications 28 November 2012 Pages: 164 - 165

33. Separation and Determination of Pyridoxine (Vitamin B6) in Serum by HPLC

    • Saeed A. Qureshi
    • Hide Huang

    Short Communications 28 November 2012 Pages: 165 - 165

34. Isotretinoin Surveillance

    • W. Downey
    • L. M. Strand
    • R. West

    Short Communications 28 November 2012 Pages: 165 - 166

35. Relative Rate of Adverse Psychological Reactions after First Time Use of Triazolam or Flurazepam

    • T. J. Quinn
    • W. Downey
    • L. M. Strand

    Short Communications 28 November 2012 Pages: 166 - 167

36. Development of Medication Monitoring Guidelines in a Home for the Aged

    • P. Bolland
    • M. Lutz
    • S. Steinberg

    Short Communications 28 November 2012 Pages: 167 - 167

37. Anabolic Steroids

    • Marc Desgagné
    • Jacques G. LeCavalier
    • Ihor Malyniwsky

    Short Communications 28 November 2012 Pages: 167 - 168

38. Monitoring of Blood Concentration of Cyclosporin and its Metabolites in Renal and Cardiac Transplant Patients

    • J. C. K. Loo
    • K. D. Gallicano
    • S. L. Jindal

    Short Communications 28 November 2012 Pages: 168 - 168